Aarti Drugs Q1 FY27 Profit Declines to ₹48.64 Cr, Revenue at ₹702.78 Cr
Aarti Drugs reported consolidated profit after tax of ₹48.64 crore for the quarter ended June 30, 2026, down from ₹50.17 crore in the prior quarter. Consolidated total income was ₹720.30 crore, a slight decrease from ₹725.90 crore.
The decrease in profit and slight dip in revenue, while not drastic, may have a moderate impact on investor sentiment.
The company reported a decline in profit after tax for the quarter compared to the previous quarter.
Aarti Drugs Limited announced its audited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors approved these results in a meeting held on Friday, July 31, 2026.
For the quarter ended June 30, 2026, the company reported a total income of ₹720.30 crore on a consolidated basis, a decrease from ₹725.90 crore in the previous quarter. Total expenses were ₹671.94 crore, compared to ₹663.34 crore in the prior quarter.
The company's profit after tax for the quarter stood at ₹48.64 crore (consolidated), a decline from ₹50.17 crore in the previous quarter. The standalone profit after tax was ₹48.64 crore. Exceptional items for the quarter included a write-off of Capital Work-in-Progress (CWIP) of ₹2.09 crore pertaining to an administrative building.
The Board meeting commenced at 2:30 PM and concluded at 5:20 PM on July 31, 2026. The financial results will be published in newspapers and uploaded on the company's website, as well as on the websites of BSE and NSE.
What to do with a filing like this
Aarti Drugs Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarti Drugs Limited. Read the original for the full detail.